LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 2 | N13 | 72 | hr | 1476 | 3812 | 3694 | 1.0319 | 1.0532 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 3 | N13 | 72 | hr | 1476 | 3761 | 3694 | 1.0181 | 1.0302 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 1 | K19 | 72 | hr | 1476 | 1204 | 3694 | 0.3259 | -0.1230 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 2 | K19 | 72 | hr | 1476 | 1247 | 3694 | 0.3376 | -0.1036 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 3 | K19 | 72 | hr | 1476 | 1159 | 3694 | 0.3138 | -0.1433 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 1 | B19 | 72 | hr | 1476 | 1296 | 3694 | 0.3508 | -0.0815 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 2 | B19 | 72 | hr | 1476 | 1129 | 3694 | 0.3056 | -0.1568 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 3 | B19 | 72 | hr | 1476 | 797 | 3694 | 0.2158 | -0.3066 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 1 | M19 | 72 | hr | 1476 | 1685 | 3694 | 0.4561 | 0.0939 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 2 | M19 | 72 | hr | 1476 | 1916 | 3694 | 0.5187 | 0.1981 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 3 | M19 | 72 | hr | 1476 | 1621 | 3694 | 0.4388 | 0.0651 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 1 | G01 | 72 | hr | 1476 | 555 | 3694 | 0.1502 | -0.4157 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 2 | G01 | 72 | hr | 1476 | 741 | 3694 | 0.2006 | -0.3318 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 3 | G01 | 72 | hr | 1476 | 692 | 3694 | 0.1873 | -0.3539 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 1 | J07 | 72 | hr | 1476 | 1754 | 3694 | 0.4748 | 0.1251 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 2 | J07 | 72 | hr | 1476 | 1934 | 3694 | 0.5235 | 0.2062 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 3 | J07 | 72 | hr | 1476 | 1852 | 3694 | 0.5014 | 0.1693 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 1 | O19 | 72 | hr | 1476 | 2377 | 3694 | 0.6435 | 0.4060 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 2 | O19 | 72 | hr | 1476 | 2425 | 3694 | 0.6565 | 0.4277 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 3 | O19 | 72 | hr | 1476 | 2640 | 3694 | 0.7147 | 0.5246 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 1 | C19 | 72 | hr | 1476 | 697 | 3694 | 0.1887 | -0.3517 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 2 | C19 | 72 | hr | 1476 | 555 | 3694 | 0.1502 | -0.4157 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 3 | C19 | 72 | hr | 1476 | 640 | 3694 | 0.1733 | -0.3774 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 1 | C19 | 72 | hr | 1476 | 540 | 3694 | 0.1462 | -0.4225 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 2 | C19 | 72 | hr | 1476 | 639 | 3694 | 0.1730 | -0.3778 |